165 related articles for article (PubMed ID: 31994460)
1. Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response.
Souid S; Aissaoui D; Srairi-Abid N; Essafi-Benkhadir K
Curr Drug Targets; 2020; 21(10):996-1007. PubMed ID: 31994460
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
4. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
Lorusso D; Scambia G; Pignata S; Sorio R; Amadio G; Lepori S; Mosconi A; Pisano C; Mangili G; Maltese G; Sabbatini R; Artioli G; Gamucci T; Di Napoli M; Capoluongo E; Ludovini V; Raspagliesi F; Ferrandina G
Ann Oncol; 2016 Mar; 27(3):487-93. PubMed ID: 26681678
[TBL] [Abstract][Full Text] [Related]
5. Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines.
Iwasaki J; Komori T; Nakagawa F; Nagase H; Uchida J; Matsuo K; Uto Y
Anticancer Res; 2019 Jul; 39(7):3553-3563. PubMed ID: 31262879
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.
Italiano A; Touati N; Litière S; Collin F; Pourquier P; Gronchi A
Cancer Med; 2018 May; 7(5):1575-1577. PubMed ID: 29656586
[TBL] [Abstract][Full Text] [Related]
7. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin in Cancers: Mechanisms and Clinical Applications.
Wang J; Wang P; Zeng Z; Lin C; Lin Y; Cao D; Ma W; Xu W; Xiang Q; Luo L; Wang W; Shi Y; Gao Z; Zhao Y; Liu H; Liu SL
Curr Pharm Des; 2022; 28(24):1949-1965. PubMed ID: 35619256
[TBL] [Abstract][Full Text] [Related]
9. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin in Ovarian Cancer: is it now a Standard of Care?
Ventriglia J; Paciolla I; Cecere SC; Pisano C; Di Napoli M; Arenare L; Setola SV; Losito NS; Califano D; Orditura M; Pignata S
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):498-503. PubMed ID: 29429842
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
13. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Patel S; von Mehren M; Reed DR; Kaiser P; Charlson J; Ryan CW; Rushing D; Livingston M; Singh A; Seth R; Forscher C; D'Amato G; Chawla SP; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Demetri GD
Cancer; 2019 Aug; 125(15):2610-2620. PubMed ID: 31173362
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
Kawaguchi K; Nakano K; Urasaki T; Fukuda N; Taira S; Ono M; Tomomatsu J; Nishizawa M; Ae K; Matsumoto S; Takahashi S
In Vivo; 2019; 33(5):1609-1614. PubMed ID: 31471412
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin for the treatment of breast cancer.
D'Incalci M; Zambelli A
Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
[TBL] [Abstract][Full Text] [Related]
16. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
Saponara M; Stacchiotti S; Gronchi A
Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
[TBL] [Abstract][Full Text] [Related]
18. An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
Ray-Coquard I
Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S3-5. PubMed ID: 21540667
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells.
Loi M; Salvatore G; Aquilano M; Greto D; Talamonti C; Salvestrini V; Melica ME; Valzano M; Francolini G; Sottili M; Santini C; Becherini C; Campanacci DA; Mangoni M; Livi L
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430780
[TBL] [Abstract][Full Text] [Related]
20. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]